Please assess the completion status of the following clinical trial:

Trial Title: A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-75 years old (including 18 and 75 years);~2. clinically diagnosed grade 2 or 3 radiation-induced lung injury;~3. the course of radiation-induced lung injury is less than 2 months;~4. ECOG 0-2;~5. the expected survival time is more than 6 months;~6. the functional level of major organs meets the following standards: ANC≥3.0×109/L，PLT≥100×109/L，Hb≥90g/L, TBIL、BUN and Cr≤1.5×ULN， ALT、AST≤2.0×ULN~7. capable of eating solid food upon enrollment;~8. subjects will voluntarily participate in this study and sign the informed consent.~Exclusion Criteria:~1. have a history of chronic bronchial acute attack or severe pulmonary heart disease;~2. pneumonectomy;~3. tumor progression;~4. severe pulmonary infection;~5. creatinine clearance rate \< 30ml/min, severe renal disease or need dialysis;~6. concomitant with other serious diseases: for example, myocardial infarction within 6 months, uncontrolled diabetes, etc., were considered not suitable for the participants in the study;~7. patients with active peptic ulcer;~8. pregnant women and patients with mental illness;~9. participating in clinical trials of other drugs within 3 months;~10. the investigator determined that subject was not suitable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pirfenidone (Type: EXPERIMENTAL): pirfenidone + basic treatment
- Controll (Type: OTHER): with basic treatment and without pirfenidone treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).